查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1473809

支原體測試市場 - 按產品類型（儀器、試劑盒和試劑、服務）、按技術（PCR、ELISA、微生物培養技術、酶法）、按應用（細胞株測試、病毒測試）、按最終用途和預測， 2024 - 2032

Mycoplasma Testing Market - By Product Type (Instruments, Kits & Reagents, Services), By Technique (PCR, ELISA, Microbial Culturing Techniques, Enzymatic Methods), By Application (Cell Line Testing, Virus Testing), By End-use & Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 205 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於細胞培養研究中支原體污染的流行以及對生物製藥和疫苗的強烈需求，支原體測試市場規模預計在 2024 年至 2032 年期間將以超過 11.9% 的複合年成長率成長。對生物製藥和疫苗不斷成長的需求是推動市場擴張的重要驅動力。生物製藥，包括單株抗體、重組蛋白和基因療法，正成為現代醫學的基石。根據世界衛生組織統計，光是2021年，全球疫苗供應量就達160億劑，價值約1,410億美元。

由於生物製藥和疫苗是使用複雜的細胞培養過程製造的，因此確保其安全性和有效性變得至關重要。支原體污染對這些產品的品質和安全構成嚴重風險。受污染的生物藥品和疫苗可能會對患者造成不利影響、監管問題以及製造商的財務損失。為了滿足監管要求並維持產品質量，生物製藥和疫苗製造商擴大投資先進的支原體檢測解決方案。這些解決方案能夠快速且準確地檢測支原體污染，同時有助於維護生物製藥和疫苗生產過程的完整性。

支原體檢測市場根據產品類型、應用、技術、最終用途和地區進行分類。

2024年至2032年，儀器產品類型細分市場的市場規模預計將以11.8%的複合年成長率大幅成長。 、準確的支原體檢測細胞培養物和生物製藥產品中的污染。這些儀器可實現高通量篩選和自動化，進而提高支原體檢測實驗室的效率和生產力。此外，創新攜帶式儀器的出現促進了現場測試，進一步縮短了周轉時間並實現了污染風險的即時監控。

從技術角度來看，酵素連結免疫吸附測定(ELISA) 領域的支原體檢測產業預計到2032 年複合年成長率將達到11.8%。製品中的支原體抗原或抗體。憑藉其高靈敏度和可擴展性，ELISA 還為研究實驗室和生物製藥生產設施中的常規支原體篩檢提供了經濟高效的解決方案。

在快速工業化、生物製藥研發投資增加以及對產品安全和品質標準意識不斷增強的推動下，亞太地區支原體檢測行業預計到 2032 年將以 12.3% 的複合年成長率成長。在政府有利措施、基礎設施發展和技術進步的推動下，中國、印度和日本等國家的生物製藥生產活動激增。此外，大量熟練勞動力和具有成本效益的製造能力的存在將進一步擴大區域市場的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 細胞培養技術的進步
      • 細胞培養物污染上升
      • 增加研發活動
      • 對快速、準確且經濟實惠的支原體檢測的需求不斷成長
    • 產業陷阱與挑戰
      • 檢測過程漫長而費力
      • 嚴格的監管場景
  • 成長潛力分析
  • 技術景觀
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按產品類型，2018 年 - 2032 年

  • 主要趨勢
  • 儀器
  • 試劑盒和試劑
    • PCR（聚合酶鍊式反應）檢測
    • 核酸檢測試劑盒
    • 污漬
    • 消除套件
    • 標準和控制
    • ELISA（酵素連結免疫吸附測定）試劑盒
    • 其他試劑盒和試劑
  • 服務

第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年

  • 主要趨勢
  • PCR（聚合酶鍊式反應）
  • ELISA（酵素連結免疫吸附測定）
  • 微生物培養技術
  • 酵素法
  • 其他技術

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

  • 主要趨勢
  • 細胞系測試
  • 病毒檢測
  • 生產單元測試結束
  • 其他應用

第 8 章：市場估計與預測：依最終用途，2018 - 2032 年

  • 主要趨勢
  • 學術研究機構
  • 細胞庫和實驗室
  • 合約研究組織
  • 製藥和生物技術公司
  • 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Becton, Dickinson, and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Bioarray
  • Eurofins Scientific
  • InvivoGen
  • Lonza Group AG
  • Merck KGaA
  • Minerva Biolabs GmbH
  • PromoCell GmbH
  • QIAGEN N.V.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 8300

Mycoplasma Testing Market size is expected to grow at over 11.9% CAGR during 2024-2032, driven by increasing prevalence of mycoplasma contamination in cell culture-based research and the strong need for biopharmaceuticals and vaccines. The growing demand for biopharmaceuticals and vaccines is a significant driver propelling the market expansion. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, are becoming the cornerstone of modern medicine. As per WHO, in 2021 alone, the global supply of vaccines amounted to 16 billion doses, valued at approximately US$ 141 billion.

As biopharmaceuticals and vaccines are manufactured using complex cell culture processes, ensuring their safety and efficacy has turned paramount. Mycoplasma contamination poses a serious risk to the quality and safety of these products. Contaminated biopharmaceuticals and vaccines can lead to adverse effects on patients, regulatory issues, and financial losses for manufacturers. To meet regulatory requirements and maintain product quality, biopharmaceutical and vaccine manufacturers are increasingly investing in advanced mycoplasma testing solutions. These solutions enable rapid and accurate detection of mycoplasma contamination while helping to safeguard the integrity of biopharmaceutical and vaccine production processes.

The mycoplasma testing market is classified based on product type, application, technique, end-use and region.

The market size from the instruments product type segment is expected to grow substantially at 11.8% CAGR from 2024 to 2032. Advanced instrumentation technologies, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer rapid and accurate detection of mycoplasma contamination in cell cultures and biopharmaceutical products. These instruments enable high-throughput screening and automation, enhancing efficiency and productivity in mycoplasma testing laboratories. Additionally, the advent of innovative portable instruments facilitates on-site testing, further reducing turnaround times and enabling real-time monitoring of contamination risks.

By technique, the mycoplasma testing industry from the enzyme-linked immunosorbent assay (ELISA) segment is poised to record 11.8% CAGR through 2032. ELISA-based assays leverage the specificity of antigen-antibody interactions to detect and quantify mycoplasma antigens or antibodies in biological samples. With its high sensitivity and scalability, ELISA also offers a cost-effective solution for routine mycoplasma screening in research laboratories and biopharmaceutical manufacturing facilities.

Asia Pacific mycoplasma testing industry is set to expand at 12.3% CAGR till 2032, driven by rapid industrialization, increasing investments in biopharmaceutical R&D, and the growing awareness about product safety and quality standards. Countries, such as China, India, and Japan are witnessing a surge in biopharmaceutical manufacturing activities, fueled by favorable government initiatives, infrastructure development, and technological advancements. Moreover, the presence of a large pool of skilled labor and cost-effective manufacturing capabilities will further augment the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Public sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Advancements in cell culture technology
      • 3.2.1.2 Rising cell culture contamination
      • 3.2.1.3 Increasing research and development activities
      • 3.2.1.4 Increasing demand for fast, accurate, and affordable mycoplasma testing
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Long and laborious detection process
      • 3.2.2.2 Stringent regulatory scenario
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Kits and reagents
    • 5.3.1 PCR (Polymerase chain reaction) assays
    • 5.3.2 Nucleic acid detection kits
    • 5.3.3 Stains
    • 5.3.4 Elimination kits
    • 5.3.5 Standards & controls
    • 5.3.6 ELISA (Enzyme-linked immunosorbent assay) kits
    • 5.3.7 Other kits and reagents
  • 5.4 Services

Chapter 6 Market Estimates and Forecast, By Technique, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 PCR (Polymerase chain reaction)
  • 6.3 ELISA (Enzyme-linked immunosorbent assay)
  • 6.4 Microbial culturing technique
  • 6.5 Enzymatic methods
  • 6.6 Other techniques

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cell line testing
  • 7.3 Virus testing
  • 7.4 End of production cells testing
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Academic research institutes
  • 8.3 Cell banks & laboratories
  • 8.4 Contract research organizations
  • 8.5 Pharmaceutical & biotechnology companies
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Becton, Dickinson, and Company (BD)
  • 10.2 Bio-Rad Laboratories, Inc.
  • 10.3 Charles River Laboratories International, Inc.
  • 10.4 Creative Bioarray
  • 10.5 Eurofins Scientific
  • 10.6 InvivoGen
  • 10.7 Lonza Group AG
  • 10.8 Merck KGaA
  • 10.9 Minerva Biolabs GmbH
  • 10.10 PromoCell GmbH
  • 10.11 QIAGEN N.V.
  • 10.12 Sartorius AG
  • 10.13 Thermo Fisher Scientific Inc.